Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kendle International Inc. (KNDL) -- Ignore unavailable to you. Want to Upgrade?

To: Alan M. Solinger who wrote (5)	2/19/1998 1:48:00 AM
From: Jeff Mulder	Respond to of 53

Interesting take on KNDL and CROs in general. Have other CROs been doing as well as KNDL over the past couple years? More importantly, can KNDL continue to knock out triple-digit growth? Their numbers for the last four quarters are extremely impressive. - Jeff

To: Alan M. Solinger who wrote (5)	2/19/1998 1:56:00 AM
From: Jeff Mulder	Read Replies (1) \| Respond to of 53

Stumbled onto KNDL tonight researching CANSLIM stocks. Here are the CANSLIM numbers for KNDL. Current (quarterly) earnings: +225% Current (quarterly) sales: +246% Annual EPS growth: 88% New products, new acquisitions, etc.: Haven't found anything here yet. Shares outstanding: 7.3 million Leadership: EPS rank of 99, RS rank of 81. Institutional ownership: 7% Market conditions: favorable Group strength: 89 Acc/dist: A PE: 52 Up/down: 2.6 These are extremely good CANSLIM numbers. My biggest complaint would be RS. It barely squeaks by the CANSLIM minimum of 80, and many CANSLIM investors only buy stocks with RS ranks of 90 or higher. But overall, very impressive. Nice breakout from a base here too. Looks like the stock is fading back to the top of the base before heading higher. - Jeff